110 related articles for article (PubMed ID: 21088497)
1. Prostate cancer genomic signature offers prognostic value.
Troutman SM; Price DK; Figg WD
Cancer Biol Ther; 2010 Dec; 10(11):1079-80. PubMed ID: 21088497
[TBL] [Abstract][Full Text] [Related]
2. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic profiling of human prostate cancer.
Taylor BS; Schultz N; Hieronymus H; Gopalan A; Xiao Y; Carver BS; Arora VK; Kaushik P; Cerami E; Reva B; Antipin Y; Mitsiades N; Landers T; Dolgalev I; Major JE; Wilson M; Socci ND; Lash AE; Heguy A; Eastham JA; Scher HI; Reuter VE; Scardino PT; Sander C; Sawyers CL; Gerald WL
Cancer Cell; 2010 Jul; 18(1):11-22. PubMed ID: 20579941
[TBL] [Abstract][Full Text] [Related]
6. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
9. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
Holcomb IN; Grove DI; Kinnunen M; Friedman CL; Gallaher IS; Morgan TM; Sather CL; Delrow JJ; Nelson PS; Lange PH; Ellis WJ; True LD; Young JM; Hsu L; Trask BJ; Vessella RL
Cancer Res; 2008 Jul; 68(14):5599-608. PubMed ID: 18632612
[TBL] [Abstract][Full Text] [Related]
10. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.
Holcomb IN; Young JM; Coleman IM; Salari K; Grove DI; Hsu L; True LD; Roudier MP; Morrissey CM; Higano CS; Nelson PS; Vessella RL; Trask BJ
Cancer Res; 2009 Oct; 69(19):7793-802. PubMed ID: 19773449
[TBL] [Abstract][Full Text] [Related]
11. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.
Williams JL; Greer PA; Squire JA
Cancer Genet; 2014; 207(10-12):474-88. PubMed ID: 25434580
[TBL] [Abstract][Full Text] [Related]
12. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization.
Fu W; Bubendorf L; Willi N; Moch H; Mihatsch MJ; Sauter G; Gasser TC
Urology; 2000 Nov; 56(5):880-5. PubMed ID: 11068328
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness.
Brezina S; Feigl M; Gumpenberger T; Staudinger R; Baierl A; Gsur A
Mutagenesis; 2020 Jul; 35(3):283-290. PubMed ID: 32255470
[TBL] [Abstract][Full Text] [Related]
14. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Graff RE; Pettersson A; Lis RT; DuPre N; Jordahl KM; Nuttall E; Rider JR; Fiorentino M; Sesso HD; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Nguyen PL; Sweeney CJ; Mucci LA;
Prostate; 2015 Jun; 75(9):897-906. PubMed ID: 25728532
[TBL] [Abstract][Full Text] [Related]
15. Copy number alterations in prostate tumors and disease aggressiveness.
Cheng I; Levin AM; Tai YC; Plummer S; Chen GK; Neslund-Dudas C; Casey G; Rybicki BA; Witte JS
Genes Chromosomes Cancer; 2012 Jan; 51(1):66-76. PubMed ID: 21965145
[TBL] [Abstract][Full Text] [Related]
16. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
[TBL] [Abstract][Full Text] [Related]
17. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.
Visakorpi T; Kallioniemi AH; Syvänen AC; Hyytinen ER; Karhu R; Tammela T; Isola JJ; Kallioniemi OP
Cancer Res; 1995 Jan; 55(2):342-7. PubMed ID: 7529134
[TBL] [Abstract][Full Text] [Related]
18. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.
Cher ML; MacGrogan D; Bookstein R; Brown JA; Jenkins RB; Jensen RH
Genes Chromosomes Cancer; 1994 Nov; 11(3):153-62. PubMed ID: 7530484
[TBL] [Abstract][Full Text] [Related]
19. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetic changes in prostatic carcinoma].
Sauter G; Bubendorf L; Moch H; Gasser TC; Mihatsch MJ
Pathologe; 1998 Jan; 19(1):63-8. PubMed ID: 9541944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
